Advanced glycation end products promote the progression of endometrial cancer via activating the RAGE/CHKA/PI3K/AKT signaling pathway
Carcinogenesis · 2025
DOI: 10.1093/carcin/bgae059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2025. Verfasst von Wan Shu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Glycation End Products, Advanced, Proto-Oncogene Proteins c-akt, Receptor for Advanced Glycation End Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, International Science and Technology Cooperation Project of Hubei Province.
Abstract (Originalsprache)
Endometrial cancer (EC) is a common malignant tumor that is closely associated with metabolic disorders such as diabetes and obesity. Advanced glycation end products (AGEs) are complex polymers formed by the reaction of reducing sugars with the amino groups of biomacromolecules, mediating the occurrence and development of many chronic metabolic diseases. Recent research has demonstrated that the accumulation of AGEs can affect the tumor microenvironment, metabolism, and signaling pathways, thereby affecting the malignant progression of tumors. However, the mechanism by which AGEs affect EC is unclear. Our research aimed to investigate how AGEs promote the development of EC through metabolic pathways and to explore their potential underlying mechanisms. Our experimental results demonstrated that AGEs upregulated the choline metabolism mediated by choline kinase alpha (CHKA) through the receptor for advanced glycation end products, activating the PI3K/AKT pathway and enhancing the malignant biological behavior of EC cells. Virtual screening and molecular dynamics simulation revealed that timosaponin A3 could target CHKA to inhibit AGE-induced progression of EC and that a newly discovered CHKA inhibitor could be a novel targeted inhibitor for the treatment of EC. This study provides new therapeutic strategies and contributes to the treatment of EC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Clinical Research Center of Cancer Immunotherapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
ORCID-Profile: Hongbo Wang
Förderung
- National Natural Science Foundation of China
- International Science and Technology Cooperation Project of Hubei Province
Zitieren
APA
Shu, W., Hua, T., Xin, X., Zhang, J., Lin, J., Shi, R., Zhao, R., Zhang, W., Dong, K. J., Wang, H., & Zhou, X. (2025). Advanced glycation end products promote the progression of endometrial cancer via activating the RAGE/CHKA/PI3K/AKT signaling pathway. Carcinogenesis. https://doi.org/10.1093/carcin/bgae059
Vancouver
Shu W, Hua T, Xin X, Zhang J, Lin J, Shi R, et al. Advanced glycation end products promote the progression of endometrial cancer via activating the RAGE/CHKA/PI3K/AKT signaling pathway. Carcinogenesis. 2025. doi:10.1093/carcin/bgae059
BibTeX
@article{Shu2025,
author = {Shu, Wan and Hua, Teng and Xin, Xiaoyan and Zhang, Jun and Lin, Jing and Shi, Rui and Zhao, Rong and Zhang, Wei and Dong, Ke-Jun and Wang, Hongbo and Zhou, Xing},
title = {Advanced glycation end products promote the progression of endometrial cancer via activating the RAGE/CHKA/PI3K/AKT signaling pathway},
journal = {Carcinogenesis},
year = {2025},
doi = {10.1093/carcin/bgae059}
}
EUVIMED